Prognostic Value and Prediction of Bleeding in Patients Undergoing Hematopoietic Stem-Cell Transplantation: A Retrospective Study of Chinese Group for Blood and Marrow Transplantation Working Party
Jiaqian Qi,Tao You,Hong Wang,Sensen Shi,Yaqiong Tang,Wei Han,Jia Chen,Yi Fan,Huiying Qiu,Xiaowen Tang,Chengcheng Fu,Xiao Ma,Feng Chen,Changgeng Ruan,De-Pei Wu,Yue Han
DOI: https://doi.org/10.2139/ssrn.3421606
2019-01-01
Abstract:Background: Hematopoietic stem-cell transplantation (HSCT) associated bleeding after transplantation is a life-threatening complication after transplantation. However, the prognostic value and prediction of HSCT associated bleeding have not been reported in large cohort studies.Methods: We did a retrospective analysis of data from 711 patients receiving HSCT from May 1, 2004 to April 1, 2012. Bleeding events were recorded during the admission. The major endpoint was 5-years overall mortality (OM). Other endpoints were nonrelapse mortality (NRM), cumulative incidence of relapse (CIR), and combined endpoints (CE). Survival of the score-based groups was evaluated using Kaplan-Meier analyses and cox regression models.Findings: HSCT patients with higher bleeding class had increased cumulative incidence of OM (HR = 10.90), NRM (HR = 14.84), CE (HR = 9.30) but not CIR. Incorporating bleeding class to a basic multivariate model increased the c-Index for predicting OM, NRM, and CE. The upgraded model with bleeding class showed better reclassification for OM, NRM, and CE compared to the basic model. Lasso regression revealed that donor basic disease, GVHD stage, platelet reconstitution, platelet transfusion refractoriness, and abnormal urine analysis were independently associated with the risk of bleeding. Divided the bleeding score derived from the model, patients in high risk group showed increased incidence of OM, NRM, and CE compared with those with low risk.Interpretation: HSCT patients with severe bleeding had increased risk of death that is attributed to higher NRM. A cross-validated bleeding risk score shows significant prognostic value in patients undergoing HSCT.Funding Statement: This work was supported by National Natural Science Foundation of China (81873432 and 81670132), grants from the Jiangsu Province of China (BE2016665, 18KJA320006 and ZDRCA2016047), Jiangsu Provincial Special Program of Social Development (SBE2016740635) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).Declaration of Interests: The authors declare no competing financial interests.Ethics Approval Statement: Inform and consent was obtained from all patients or their immediate family members. All protocols are conformed to the guidelines with the ethic committee of Soochow University and in accordance with the Declaration of Helsinki.